Beam Therapeutics (BEAM)Chief Medical Officer sold ~$18K

~$18K

Approx. value · 876 sh @ $20.12

65K

Holds after · shares reported

Traded

Jul 3, 2025

Filed

Jul 3, 2025

The story around this disclosure

Every dated public record OQRO holds about the company from 60 days before to 120 days after, oldest first. It shows what was going on; none of it is a stated reason for the trade.

1. Jul 1, 2025InsiderOfficer sold ~$6.3K of BEAM shares in the open market
2. Jul 3, 2025 · this disclosureInsiderOfficer sold ~$18K of BEAM shares in the open market

What came next

1. Jul 30, 2025Insider10% owner sold ~$992K of BEAM shares in the open market

How to read SEC Form 4

Form 4 is the filing that officers, directors and owners of more than 10% of a US-listed company must send to the SEC within two business days after they buy, sell or otherwise change their holding of the company's stock.

Full guide: What is an SEC Form 4?

What else is on file for Beam Therapeutics

For Beam Therapeutics, OQRO holds 1 insider filing (SEC Form 4 or Form 144) and 5 fund holdings reports (13F) dated in the last 90 days.

These are records OQRO holds, counted by their date, not a measure of how much trading took place. Routine paperwork such as option exercises and tax withholding is left out. Everything for the company is on its BEAM page.

Other recent filings by Amy Simon, Chief Medical Officer

• SEC Form 4 at Beam Therapeutics (BEAM)Jul 3, 2025
• SEC Form 4 at Beam Therapeutics (BEAM)Apr 4, 2025
• SEC Form 4 at Beam Therapeutics (BEAM)Apr 4, 2025

The full history of Amy Simon, Chief Medical Officer is on the profile page.

How this filing works

• SEC Form 4
• Open-market purchase
• Rule 10b5-1 trading plans

Other disclosures at Beam Therapeutics

• SEC Form 4Oct 2, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 14, 2026
• SEC Form 13F-HRAug 13, 2026

Everything OQRO holds on this company is on its BEAM page.